Total Payments
$17,572
2024 Payments
$792.58
Companies
50
Transactions
896
Medicare Patients
3,692
Medicare Billing
$201,235
Payment Breakdown by Category
Food & Beverage$17,278 (98.3%)
Education$294.30 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,278 | 870 | 98.3% |
| Education | $294.30 | 26 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $3,975 | 173 | $0 (2024) |
| Novo Nordisk Inc | $2,827 | 136 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,340 | 72 | $0 (2022) |
| Amgen Inc. | $1,282 | 64 | $0 (2022) |
| ABBVIE INC. | $1,135 | 51 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,077 | 58 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $994.98 | 48 | $0 (2021) |
| PFIZER INC. | $642.56 | 49 | $0 (2021) |
| Lilly USA, LLC | $463.27 | 26 | $0 (2023) |
| Amarin Pharma Inc. | $345.83 | 22 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $792.58 | 16 | Novo Nordisk Inc ($344.50) |
| 2023 | $432.41 | 11 | AstraZeneca Pharmaceuticals LP ($186.16) |
| 2022 | $1,476 | 63 | AstraZeneca Pharmaceuticals LP ($350.56) |
| 2021 | $2,723 | 157 | AstraZeneca Pharmaceuticals LP ($571.13) |
| 2020 | $2,607 | 144 | AstraZeneca Pharmaceuticals LP ($745.45) |
| 2019 | $2,969 | 160 | AstraZeneca Pharmaceuticals LP ($477.98) |
| 2018 | $3,561 | 173 | Novo Nordisk Inc ($712.24) |
| 2017 | $3,010 | 172 | Novo Nordisk Inc ($692.70) |
All Payment Transactions
896 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/17/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $6.03 | General |
| Category: Diabetes | ||||||
| 07/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.57 | General |
| 06/27/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $124.82 | General |
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.03 | General |
| 05/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Cardio-renal | ||||||
| 04/25/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $4.79 | General |
| Category: Diabetes | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $101.61 | General |
| Category: Respiratory | ||||||
| 02/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $79.78 | General |
| Category: Obesity | ||||||
| 02/07/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 02/07/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 02/07/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 02/07/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $29.03 | General |
| 10/26/2023 | AbbVie Inc. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $93.07 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/19/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $97.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Cardio-renal | ||||||
| 08/23/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 05/03/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/02/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $98.51 | General |
| Category: Diabetes | ||||||
| 04/27/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: NEUROSCIENCE | ||||||
| 04/07/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.88 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 11 | 723 | 866 | $142,585 | $50,643 |
| 2021 | 17 | 1,168 | 1,530 | $120,437 | $69,260 |
| 2020 | 20 | 1,801 | 2,354 | $152,651 | $81,332 |
Total Patients
3,692
Total Services
4,750
Medicare Billing
$201,235
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 152 | 188 | $66,574 | $22,382 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 152 | 212 | $52,361 | $15,469 | 29.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 52 | 52 | $11,318 | $6,613 | 58.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 21 | 23 | $1,495 | $1,414 | 94.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 22 | 22 | $1,430 | $1,401 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 42 | 46 | $1,840 | $1,339 | 72.8% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 64 | 77 | $2,310 | $724.76 | 31.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 20 | $3,390 | $545.50 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 143 | 169 | $845.00 | $504.00 | 59.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 40 | 41 | $382.00 | $135.55 | 35.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 16 | 16 | $640.00 | $113.96 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 206 | 386 | $63,690 | $32,976 | 51.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 82 | 82 | $10,470 | $10,342 | 98.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 71 | $14,910 | $9,147 | 61.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 77 | 91 | $11,375 | $4,530 | 39.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 24 | 24 | $4,325 | $4,054 | 93.7% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 38 | 38 | $2,340 | $2,340 | 100.0% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 105 | 131 | $3,930 | $1,272 | 32.4% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 16 | 16 | $1,465 | $1,225 | 83.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 219 | 331 | $1,655 | $993.00 | 60.0% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2021 | 99 | 106 | $2,165 | $685.82 | 31.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 39 | 39 | $1,560 | $668.82 | 42.9% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2021 | 17 | 17 | $270.00 | $256.35 | 94.9% |
| 81002 | Urinalysis, manual test | Office | 2021 | 70 | 74 | $618.00 | $254.92 | 41.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 27 | 27 | $1,080 | $215.10 | 19.9% |
About Dr. Douglas Crawford, D.O
Dr. Douglas Crawford, D.O is a Family Medicine healthcare provider based in Richland, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912944786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Crawford, D.O has received a total of $17,572 in payments from pharmaceutical and medical device companies, with $792.58 received in 2024. These payments were reported across 896 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($17,278).
As a Medicare-enrolled provider, Crawford has provided services to 3,692 Medicare beneficiaries, totaling 4,750 services with total Medicare billing of $201,235. Data is available for 3 years (2020–2022), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Richland, WA
- Active Since 06/01/2006
- Last Updated 11/29/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1912944786
Products in Payments
- FARXIGA (Drug) $2,524
- Ozempic (Drug) $1,131
- SYMBICORT (Drug) $753.35
- JARDIANCE (Drug) $668.02
- Tresiba (Drug) $508.85
- Aimovig (Biological) $503.96
- TRELEGY ELLIPTA (Drug) $484.10
- INVOKANA (Drug) $483.98
- Victoza (Drug) $470.89
- XARELTO (Drug) $397.62
- UBRELVY (Drug) $383.83
- BREZTRI (Drug) $381.67
- Vascepa (Drug) $345.83
- ELIQUIS (Drug) $299.30
- QULIPTA (Drug) $297.06
- BEXSERO (Biological) $286.56
- SHINGRIX (Biological) $270.68
- ENTRESTO (Drug) $265.06
- Saxenda (Drug) $254.88
- Livalo (Drug) $253.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Richland
Martin Coker, M.d, M.D
Family Medicine — Payments: $10,688
Family Medicine $10,688
Dr. Douglas Hargrave, D.o, D.O
Family Medicine — Payments: $8,275
Family Medicine $8,275
Mr. Matthew Lawrence, Md, MD
Family Medicine — Payments: $8,057
Family Medicine $8,057
Dr. Scott Kelly, M.d, M.D
Family Medicine — Payments: $4,838
Family Medicine $4,838
David Merkley, Md, MD
Family Medicine — Payments: $3,884
Family Medicine $3,884
Dr. James Polk, M.d, M.D
Family Medicine — Payments: $3,668
Family Medicine $3,668